Halozyme Therapeutics, Inc.
11388 Sorrento Valley Road
San Diego
California
92121
United States
Tel: 858-794-8889
Fax: 858-259-2539
Website: http://www.halozyme.com/
Email: hr@halozyme.com
575 articles about Halozyme Therapeutics, Inc.
-
Halozyme to Participate in Upcoming Investor Conferences - February 27, 2024
2/27/2024
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences.
-
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
2/20/2024
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the fourth quarter and full year ended December 31, 2023 and provided an update on its recent corporate activities and outlook.
-
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
2/8/2024
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2023 financial and operating results on Tuesday, February 20, 2024, following the close of trading.
-
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1/29/2024
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received European Commission (EC) approval for HYQVIA® [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme's ENHANZE® drug delivery technology as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilization with intravenous immunoglobulin therapy (IVIG).
-
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
1/18/2024
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for VYVDURA ® (efgartigimod alfa and hyaluronidase-qvfc) injection co-formulated with Halozyme's ENHANZE® drug delivery technology for subcutaneous (SC) use for the treatment of adult patients with generalized myasthenia gravis (gMG).
-
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1/16/2024
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received U.S. Food and Drug Administration (FDA) approval for HYQVIA® [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme's ENHANZE® drug delivery technology for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.
-
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
1/16/2024
Halozyme Therapeutics, Inc. announced that Roche received European Commission marketing authorization of Tecentriq® SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20.
-
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
1/12/2024
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it will host an Investor Business Forum and Long-Term Outlook Call on Wednesday, January 17, 2024 at 5:30 a.m. PT / 8:30 a.m. ET.
-
Halozyme to Present at Upcoming Investor Conferences - November 27, 2023
11/27/2023
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the senior leadership team are scheduled to present and host investor meetings at the following investor conferences.
-
Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis
11/16/2023
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received European Commission (EC) approval of VYVGART® SC (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE® for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
-
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease
11/6/2023
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals that provides Acumen access to Halozyme's ENHANZE® drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery, for a single target.
-
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
11/6/2023
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the third quarter ended September 30, 2023 and provided an update on its recent corporate activities and outlook.
-
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
11/6/2023
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics Inc.
-
Halozyme To Report Third Quarter 2023 Financial and Operating Results
10/30/2023
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2023 financial and operating results on Monday, November 6, 2023, following the close of trading.
-
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma
10/19/2023
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb (BMS) reported positive topline results from the Phase 3 CheckMate-67T trial evaluating a subcutaneous (SC) formulation of Opdivo (nivolumab) with ENHANZE® in patients with advanced or metastatic clear cell renal cell carcinoma.
-
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference
10/16/2023
Halozyme Therapeutics, Inc. will present the positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds, at the 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference.
-
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery
10/16/2023
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds.
-
Halozyme to Present at Upcoming September 2023 Investor Conferences
8/31/2023
Halozyme Therapeutics, Inc. announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences.
-
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
8/29/2023
Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC, using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency in Great Britain.
-
Halozyme Reports Second Quarter 2023 Financial and Operating Results
8/8/2023
Halozyme Therapeutics, Inc. reported its financial and operating results for the second quarter ended June 30, 2023 and provided an update on its recent corporate activities and outlook.